Early prediction of preeclampsia in pregnancy with circulating cell-free RNA

Mira N. Moufarrej[1], Sevahn K. Vorperian[2], Ronald J. Wong[3], Ana A. Campos[3], Cecele C. Quaintance[3], Rene V. Sit[4], Michelle Tan[4], Angela M. Detweiler[4], Honey Mekonen[4], Norma F. Neff[4], Maurice L. Druzin[5], Virginia D. Winn[5], Gary M. Shaw[3], David K. Stevenson[3], Stephen R. Quake[1,4,6,*]

[1] Department of Bioengineering, Stanford University, Stanford, CA USA 94305
[2] Department of Chemical Engineering, Stanford University, Stanford, CA USA 94305
[3] Department of Pediatrics, Stanford University School of Medicine, Stanford, CA USA 94305
[4] Chan Zuckerberg Biohub, Stanford, CA USA 94305
[5] Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA USA 94305
[6] Department of Applied Physics, Stanford University, Stanford, CA USA 94305

* Corresponding author: steve@quake-lab.org

Abstract

Liquid biopsies that measure circulating cell-free RNA (cfRNA) offer an unprecedented opportunity to noninvasively study the development of pregnancy-related complications and to bridge gaps in clinical care. Here, we used 404 blood samples from 199 pregnant mothers to identify and validate cfRNA transcriptomic changes that are associated with preeclampsia (PE), a multi-organ syndrome which is the second largest cause of maternal death globally. We find that changes in cfRNA gene expression between normotensive (NT) and preeclamptic mothers are striking and stable early in gestation, well before the onset of symptoms. These changes are enriched for genes specific to neuromuscular, endothelial, and immune cell types and tissues that reflect important aspects of PE physiology and suggest new hypotheses for disease progression. This enabled identification and independent validation of a panel of 18 genes whose measurement between 5–16 weeks of gestation can form the basis of a liquid biopsy test that would identify mothers at risk of PE well before the clinical symptoms manifest themselves. Finally, we demonstrate that cfRNA changes reflect the multifactorial nature of PE and provide a means to non-invasively monitor maternal organ health. Tests based on these observations could help predict and manage who is at risk for PE, an important and until now unachieved objective for obstetric care.

Introduction

Advances in obstetrics and neonatology have significantly mitigated many of the adverse pregnancy outcomes related to preterm birth (PTB) and preeclampsia (PE) [1,2]. Nonetheless, the standards of care implemented today focus on how to treat a mother and child once a complication has been diagnosed, proving both insufficient and costly [3–6]: PE and related hypertensive disorders cause 14% of maternal deaths each year globally, second only to hemorrhage [7], and cost nearly $2B in care in the first year following delivery [5]. Worse, 3 out of 5 maternal deaths in the US are preventable and often associated with a missed or delayed complication diagnosis [8]. Such outcomes highlight the need for novel tools that would aid in identifying which mothers are at risk for hypertensive diseases, such as PE, before clinical presentation. Indeed, early prediction, which

has not been achieved to date, may enable prevention or reduction of a pregnant mother's risk of developing PE [9,10] if coupled with appropriate treatment.

PE is a leading pregnancy-related complication that globally affects 4–5% of pregnancies [11–13] and is associated with a significant increase in adverse maternal and perinatal outcomes [14–18]. Long-term, PE presents an increased maternal risk for cardiovascular [19,20] and kidney [21,22] diseases. Formally defined as new-onset hypertension with proteinuria or other organ damage (e.g., liver, brain) occurring after 20 weeks of gestation [23], PE can clinically manifest anytime thereafter, including into the post-partum period [24]. Detection and diagnosis have proven challenging both because early signs such as headaches and nausea can be easily confused with generalized pregnancy discomfort and because PE shares many signs and symptoms with other common complications like gestational thrombocytopenia and chronic hypertension.

To date, no recommended test exists that can predict the future onset of PE early in pregnancy [9]. Investigational approaches that measure biochemical signals including the measurement of two angiogenic factors (soluble fms-like tyrosine kinase-1 (sFlt1), placental growth factor (PlGF)) in the second and third trimesters [25,26] have at best only moderate positive predictive values (8–33%) [27]. A clinical test could guide the prophylactic use of low-dose aspirin, which has been shown to safely reduce the risk of PE if initially administered before 16 weeks of gestation [10,28,29]. Liquid biopsies that measure plasma cell-free RNA (cfRNA) suggest a means to bridge this gap in clinical care; however, until recently, such work often failed to progress beyond initial discovery [30]. Recent efforts have instead either focused on confirmation of PE at clinical diagnosis [31,32] or on limited individuals earlier in pregnancy with encouraging but unvalidated results [33]. Consequently, the prediction of PE early in gestation, before symptoms present, when such a test would be most useful to guide the prophylactic use of potential therapeutics remains a key objective to improve obstetric care [9].

Clinical care may also be improved by a better understanding of PE's pathogenesis. PE is which is specific to humans [34] and a few non-human primates [35], and consequently, elucidating its pathogenesis has proved challenging. Broadly, it is accepted that PE occurs in two stages – abnormal placentation early in pregnancy followed by systemic endothelial dysfunction [15,34,36]. Because PE can clinically present any time after 20 weeks of gestation and with a diversity of symptoms, significant effort has been made to subclassify the disease based upon the timing of onset as a proxy for pathology [37,38]; however, debate over the significance of such subtyping is ongoing [34,36,39,40]. Separate efforts have focused on subtyping PE molecularly using placental gene expression and histology [41,42]. Since cfRNA is derived from many tissues in the body [43,44], noninvasive liquid biopsies present a potential means to indirectly observe pathogenesis in real time and to identify physiological changes associated with PE for proposed subtypes both prior to and at diagnosis.

Here, we report that cfRNA transcriptomic changes can distinguish between normotensive (NT) and PE pregnancies throughout the course of pregnancy, irrespective of PE subtype. Interestingly, the majority of these cfRNA changes are most striking early in pregnancy – well before the onset of symptomns - suggesting that the identified cfRNA signal may correlate with PE pathogenesis, which is thought to also occur at this time. Indeed, gene ontology (GO) and tissue and cell type of origin analyses identified pathways, tissues, and cell types that both reflect known PE physiology

and suggest new means to stratify the disease. These observations enabled us to identify and
independently validate a panel of 18 genes that when measured between 5–16 weeks of gestation
form a predictive signature of which mothers are at risk for developing PE. Finally, we demonstrate
that cfRNA signals reflect the multifactorial nature of PE and provide a means to noninvasively
monitor maternal organ health. Taken together, these results show that cfRNA measurements can
form the basis for clinically relevant tests that would predict PE months before presentation,
manage who is at risk for specific organ damage, and help characterize the pathogenesis of PE in
real time.
100
101 **Results**
102
Clinical study design
To identify changes associated with PE well before traditional diagnosis, we designed a
prospective study and recruited pregnant mothers at their first clinical visit to Stanford's Lucile
Packard Children's Hospital, between 5–12 weeks of gestation, of which 131 were included in this
study (94 NT, 37 with PE). For each participant, we analyzed cfRNA for samples collected before
or at 12 weeks, between 13-20 weeks, and at or after 23 weeks of gestation, and post-partum (0–4
weeks after delivery). We then split this larger group into Discovery (n = 88, [60 NT, 28 with PE])
and Validation 1 (n = 43, [34 NT, 9 with PE]) cohorts. We also obtained samples from an
independent cohort collected at several separate institutions (Validation 2), which consisted of 89
samples collected prior to 16 weeks of gestation from 87 mothers (61 NT, 26 with PE) (Fig 1A).
113
For all cohorts, we included individuals of diverse racial and ethnic backgrounds in approximately
matched proportions across NT and PE groups (Table S1). We recorded maternal pre-pregnancy
and pregnancy characteristics, and defined a pregnancy as NT if it was both uncomplicated and
went to full-term ($\geq$ 37 weeks) or as PE with or without severe features based on current guidelines
(see Methods). For mothers who developed PE, all antenatal blood samples were collected prior
to diagnosis.
120
121 Our final analysis included a subset of those samples which passed pre-defined quality metrics
122 (Supp. note 1, Methods, Fig S1). After confirming sample quality, 404 samples from 199 mothers
123 (142 NT, 57 with PE) were included in the final analysis (Table S2). Specifically, 209, 106, and
124 89 samples from 73, 39, and 87 participants (49, 32, 61 NT; 24, 7, 26 with PE) were included in
125 Discovery, Validation 1, and Validation 2, respectively (RNAseq).
126
Across gestational timepoints in all cohorts, we found no significant difference in sampling time
between PE and NT groups (p $\geq$ 0.26, 0.11, 0.46). Known risk factors for PE, such as pre-
pregnancy maternal body mass index (BMI), maternal age, and gravidity followed expected trends.
BMI specifically was significantly different between PE and NT groups in Discovery cohort alone
(p = 0.02, 0.45, NA) while maternal age and gravidity were not (p $\geq$ 0.29, 0.16, 0.2) (Fig 1B, Table
S1). History of PTB and mode of delivery were significantly different between NT and PE groups
only for Validation 2. Other demographic factors like race, ethnicity, and nulliparity differed
across cohorts but not between case groups within each cohort (adjusted p $\leq$ 0.05, chi-squared test
for categorical or ANOVA for continuous variables with Bonferroni correction, Table S1).
136

In mothers who later developed PE, we observed no significant difference (p = 0.14, 1.0, 0.4) in
gestational age at onset between those who did not experience severe symptoms (n = 11, 4, 3*) as
compared with those with did experience severe (n = 13, 3, 13*) symptoms (Fig 1C). Furthermore,
21 mothers who developed PE also delivered preterm (n = 9, 1, 11) as compared with no mothers
in the NT group as reflected by significantly different gestational ages at delivery (p = 10^{-7}, 0.04,
10^{-9}, one-sided test) (Fig 1D) and lower fetal weight at delivery (Table S1), which was consistent
with epidemiological evidence that PE increases the risk of spontaneous or indicated preterm
delivery [5,27] (values reported as Discovery, Validation 1, Validation 2, Mann-Whitney rank test
unless otherwise specified, * denotes data were incomplete for specified cohort).
146
147   *Identification of cfRNA changes across gestation in mothers who developed PE*
148
There were 544 differentially expressed genes (DEGs) that differed across gestation and post-
partum between mothers who later developed PE with or without severe features as compared with
NT mothers who did not experience complications (adjusted p ≤ 0.05, see Methods and
Supplementary Note 2). Most DEGs (498) were annotated as protein-coding, and a small fraction
(43, 8%) were other types including 11 mitochondrial t-RNAs, 6 long non-coding RNAs, 8
pseudogenes, and 1 small nucleolar RNA (snoRNA).
155
To further understand when these changes occur during gestation, we estimated the log fold-
change (logFC) for each gene by each gestational time point as well as post-partum. We observed
that these gene changes occurred most strikingly before 20 weeks of gestation as indicated by a
clear bimodal distribution with two peaks centered around logFC of +0.8 and -0.6 (Fig 2A). We
also found that gene changes were also most stable before 20 weeks of gestation where over 50%
of genes had a coefficient of variation (CV) < 1 as compared to 31% at or after 23 weeks of
gestation and 36% at post-partum (Fig S2A).
163
We then asked whether a subset of gene changes approximately proportional in number to total
sample number (n = 49, 49, 57, 46 for each time point) was sufficient to segregate PE (n = 13, 16,
20, 17) and NT (n = 36, 33, 37, 29) samples across gestation. We found that 24-32 genes were
sufficient to separated PE and NT samples across gestation and at post-partum with good
specificity (86% [75–93%], 79% [66–88%], 97% [90–100%], and 90% [78–96%]) and sensitivity
(85% [64–95%], 88% [69–96%], 65% [47–80%], and 71% [51–86%]) (Fig 2B, S2B, All values
reported for ≤12 weeks, 13-20 weeks, ≥23 weeks of gestation and post-partum, [90% CI]) (See
also Fig S3, File S1).
172
Nearly all 544 DEG changes showed excellent agreement in both Validation cohorts as compared
to Discovery across gestation but not post-partum. Specifically, more than 82% and 92% of genes
across gestation had the same logFC sign with a spearman correlation of at least 0.67 and 0.71 for
Validation 1 and 2 respectively (p<10^{-15}) as compared with 60% and 0.35 post-partum (Fig 2C,
S2C). Finally, we asked whether symptom severity (without or with severe features) correlated
with logFC magnitude for these 544 DEGs common to both PE subtypes. We found that on
average, symptom severity did not influence logFC magnitude as reflected by a slope of nearly 1
across gestation and post-partum (Fig S2E).
181
cfRNA changes reflect disease pathophysiology in mothers who developed PE

The 544 identified DEGs could be well categorized into two longitudinal trends (Fig 2D, S4A,C).
Resembling a valley or V-shape, the first trend (Group 1) described the longitudinal behavior of
216 genes (40%), for which measured levels were reduced in PE samples (-1.3x to -1.5x) across
gestation with a minimum between 13–20 weeks. Peaking in early gestation before 20 weeks
(1.75x), the second trend (Group 2) described the behavior of 328 genes (60%) that had
significantly elevated levels in PE samples before 20 weeks and to a lesser extent after 23 weeks
of gestation (1.3x). For Group 1 but not 2, gene changes were far less evident post-partum and
trended toward no difference between PE and NT, which may reflect a placental contribution to
DEG levels.

Approximately 13% of DEGs were tissue or cell-type specific (Fig 2E). Genes that were decreased
in PE across gestation (Group 1) were broadly enriched for the immune system, whereas, those
genes increased in PE across gestation (Group 2) were enriched for nervous, muscular, endothelial,
and immune contributions as reflected by cell-type (adjusted $p \leq 0.05$, hypergeometric test) and
pathway enrichment (adjusted $p \leq 0.05$, hypergeometric test) (Fig S2E, Table S3). Consistent with
current understanding of the pathogenesis of PE, we identified a strong endothelial-linked signal
underscored by contributions from capillary aerocytes ($p = 0.03$), an endothelial cell-type specific
to the lungs [45], platelets ($p = 10^{-33}$), and several platelet related pathways like platelet degranulation
and platelet activation, signaling, and aggregation ($p \leq 10^{-8}$) among others.

Surprisingly, we also found significant, elevated nervous and muscular contributions for PE as
emphasized by contributions from excitatory neurons ($p = 0.02$), oligodendrocytes ($p = 0.005$),
and smooth muscle ($p = 0.0003$) and terms like muscle contraction and dilated cardiomyopathy ($p
\leq 0.02$). The immune system also contributes to both elevated (e.g., mesenchymal stem cells, total
PBMCs) and decreased (granulocytes, T-cells) changes across gestation. Genes in both groups
were enriched for signaling pathways (i.e., secretion by cell, integrin-mediated signaling pathway,
regulation of I-kappaB kinase, NF-kappaB signaling). Group 2 was also enriched for cellular
compartments such as the cell periphery, cell junctions, and extracellular space, consistent with
reports that PE may be associated with signaling from the fetoplacental complex [46]. Finally, DEGs
were broached enriched for genes previously implicated in PE [47] (30 gene overlap, $p = 0.006$,
hypergeometric test) (Table S3).

A machine-learning classifier predicts risk of PE on or before 16 weeks of gestation

Since gene changes associated with PE pathogenesis across gestation are readily detected
irrespective of symptom severity, we sought to build a classifier that could identify mothers at risk
of PE at or before 16 weeks of gestation (Supplementary Note 2, Fig S2E). We trained a logistic
regression model on the Discovery cohort (n = 61 NT, 24 PE samples). After training, the final
model performed well with a near perfect AUROC (0.99 [0.99–0.99]), good specificity (85% [77–
91%]), and perfect sensitivity (100% [92-100%]) (Fig 3A, Table 1). We then tested this model on
Validation 1 (n = 35 NT, 8 PE) and two other independent cohorts, which were collected at separate
institutions: Validation 2 (n = 61 NT, 28 PE samples) and Del Vecchio and colleagues [33] cohort (n
= 8 NT, 5 with PE, 7 with gestational diabetes, 2 with chronic hypertension). Across these cohorts,
the final model once again performed well with consistent AUROC (0.71 [0.70-0.71], 0.72 [0.71–
0.72], 0.74 [0.73–0.74]), sensitivity (75% [46–92%], 56% [42-72%], 60% [26–87%]) and

specificity (56% [43–70%], 69% [59-78%], 100% [89–100%]) (All reported as Validation 1,
Validation 2, Del Vecchio) (Fig 3A, Table 1).
231
Next, we inspected erroneously classified samples from the Validation 2 and Del Vecchio cohorts.
For false negatives in Validation 2 and Del Vecchio, we find a shift to later gestational ages at
collection (13.5 ± 2, 12.5 ± 2 weeks) as compared to PE samples that were correctly classified (12
± 2, 12 ± 0 weeks; mean ± SD for Validation 2, Del Vecchio) (Fig S5A). This suggests that in
practice, there may an optimal collection window to reduce false negatives. Indeed, if we only
consider samples before 14 weeks of gestation, we observe a 9% and 15% increase in sensitivity
with corresponding AUROC values of 0.73 and 0.90 for Validation 2 and Del Vecchio
respectively. There were no false positives in the Del Vecchio cohort, suggesting that the model
can distinguish between PE and other risks like chronic hypertension or gestational diabetes. The
model also proved well-calibrated estimating a slightly elevated probability of PE for gestational
diabetes (0.15 ± 0.08) and chronic hypertension (0.18 ± 0.13) – known PE risk factors [48–54] – as
compared to the estimate for NT samples (0.09 ± 0.08) (mean ± SD, Fig S5B). These elevated
probabilities for other risk factors impacted the test's AUROC (0.74 [0.73-0.74] as compared to
0.8 [0.79-0.8] for only PE vs NT samples, Table 1) (all reported as value, [90% CI]).
246
Finally, we inspected the 18 genes (Fig 3B, Table S4) used by the model to yield probability
estimates. Eight genes were annotated in the Human Protein Atlas (HPA)[55] as enhanced or
enriched in the placenta (FAM46A, MYLIP), neuromuscular (CAMK2G, NDUFV3, PI4KA,
PRTFDC1) and immune systems (RNF149, TRIM21). Univariate analysis further confirmed that
9 of the gene trends (i.e., decreased or increased gene levels in PE) observed in the Discovery
dataset are upheld in Validation 2 (adjusted p ≤ 0.05, one-sided Mann-Whitney rank test) (Fig 3B).
We also found that the majority of models trained using a subset of the 18 initial genes can predict
future PE onset with varying performance. Notably, performance improved across all metrics
(sensitivity, specificity, and AUROC) as we increased the number of genes included for model
training (Table S5, Fig S5C).
257
The multifactorial nature of PE and maternal organ health is reflected in cfRNA
We next wondered whether cfRNA measurement reflects the multifactorial nature of PE. We
identified 503 DEGs (adjusted p ≤ 0.05) that differed across gestation between mothers who later
developed PE with as compared to without severe symptoms. Since there were no significant
differences in symptom severity as related to timing of PE onset (Fig 1C), we believe that our
observations contrasting PE with and without severe symptoms are not obscured by differences in
PE-onset type. As before, most DEGs (484) were annotated as protein-coding, and a small fraction
(18, 4%) were other types including 12 pseudogenes and 4 long non-coding RNAs.
266
We observed that DEGs could be well categorized into 4 longitudinal trends (Fig 4A, S4B,D).
Two groups (Group 1, 3) described the temporal behavior of 217 genes (44%), for which measured
levels were either consistently increased (Group 1) or reduced (Group 3) in PE with as compared
to without severe symptoms (±1.8x) across gestation and trended towards no change post-partum.
In contrast, Groups 2 and 4 (286 genes, 56%) changed signs in mid-gestation beginning as slightly
elevated (Group 2, 1.2x) or decreased (Group 4, -1.2x) in severe PE and then moving to decreased
(Group 2, -1.4x) or unchanged (Group 4, 1x) at ≥23 weeks of gestation.

Analysis of the enriched cell types and tissues of origin for each of these groups revealed that
elevated gene differences in severe PE were driven by contributions from endothelial cells and the
adaptive immune system (bone marrow). In contrast, genes that changed signs over gestation were
enriched for innate immune cell types (e.g., granulocytes and neutrophils for Group 2, thymus for
Group 4) (Table S6). Quantifying total cfRNA signal confirmed an increased bone marrow signal
for only severe PE across gestation and a decreased granulocyte signal for only PE without severe
features at ≤12 weeks of gestation (Fig 4B). Gene ontology analysis further revealed pathways
specific to genes that were only decreased for severe PE in early gestation (Group 4) like axon
guidance, nervous development, and metabolism of RNA (adjusted $p < 0.05$).

We next investigated whether it might be possible to monitor organ health noninvasively focusing
on eight organ systems (Fig 4B) relevant to PE presentation with consequences such as proteinuria,
impaired liver function, renal insufficiency, and epilepsy. We found striking shifts in total
contributions for all systems. We observed an increased astrocyte signal before 20 weeks of
gestation and decreased oligodendrocytes and excitatory neurons at ≥23 weeks of gestation for all
PE relative to NT (Fig 4B, 1st row). Although placental contributions increased over pregnancy
with a peak in late gestation as expected, placental tissue and syncytiotrophoblast contributions
were reduced for PE pregnancies before 20 weeks of gestation. Finally, we observed a decreased
signal in hepatocyte, kidney, endothelial cell, and smooth muscle signatures across gestation and
increased platelet signal before 12 weeks of gestation for PE. These tissue and cell type specific
changes are both consistent with common PE pathogenesis and the specific, prominent diagnoses
in our cohort (e.g., thrombocytopenia, proteinuria, impaired liver function, renal insufficiency).

Discussion
Noninvasive measurements of the cf-transcriptome present an opportunity to study human
development and disease from any organ at a molecular scale. Here, we showed that circulating
cfRNA measurements taken during pregnancy can clearly distinguish between PE and NT
pregnancies. We found that the most striking differences occur early on and broadly showed no
reproducible difference at post-partum, consistent with known PE etiology, namely that the
placenta drives the disease process [34,36]. We next validated these changes using two separate
cohorts (Validation 1 and 2) and explored their physiological relevance.

Our findings provide molecular evidence supporting generally accepted physiological
understanding of PE pathogenesis: early abnormal placentation and systemic endothelial
dysfunction [34]. Early in gestation, we observe a reduced placental signal for PE regardless of onset
type or symptom severity. Concurrently, platelets and endothelial cells drive cfRNA changes in
all PE as compared to NT and between PE with or without severe symptoms especially before 20
weeks of gestation. Increases in cell-type specific cfRNA may occur through signaling and
secretion by cells, as underscored by functional enrichment analysis. The innate and adaptive
immune system also heavily contribute to cfRNA changes in PE with clear, marked shifts related
to bone marrow, T-cells, B-cells, granulocytes, and neutrophils, consistent with previous studies
on the maternal-placental interface and PE [34,56–58] .

PE is a broad and complex syndrome. Because the complication can present clinically across more
than 20 weeks with a diversity of symptoms, significant effort has been made to subclassify the
disease based on timing of onset. Used as a proxy for hypothesized pathogenesis, the timing of PE

onset subdivides the disease into 'placental' early-onset PE (occurring before 34 weeks of
gestation) and 'maternal' late-onset PE (occurring on or after 34 weeks) [34,37,59]. However, early-
and late-onset PE may represent a spectrum of disease severity that corresponds with timing of
onset and may lead to additional pregnancy complications, such as intrauterine growth restriction
(IUGR) [34,36,38,39]. Indeed, some evidence such as transcriptional profiling of whole blood drawn at
diagnosis suggests a common gene signature for both subtypes [40]. Our findings further corroborate
a common signature across onset types and suggest that PE may be better stratified based on
symptom severity.
328
Indeed, PE may be best subtyped molecularly. Given the diversity of clinical presentations, we
propose a novel, noninvasive means of monitoring a mother's risk of specific organ damage,
common in PE. The cfRNA changes we characterized here reflect dysfunction in at least five organ
systems (brain, liver, kidney, muscle, bone marrow), and can in some cases further distinguish
between PE with or without severe symptoms. As a molecular lens into maternal health, liquid
biopsies present an opportunity as both a research and clinical tool to learn about the pathogenesis
of a human disease in humans and as a predictor of maternal health. Here, we have shown proof
of principle that cfRNA measurements can form the basis for a robust liquid biopsy test, which
predicts PE very early in gestation and if validated in controlled clinical studies, could help
discover and manage those at risk for PE. Such a test could serve as a complement to recent efforts
based on clinical and laboratory data[60], and even be coupled with tests taken later during gestation.
We further demonstrated that cfRNA measurements reflect who is at risk for specific organ
damage. Together, these results form the basis for a series of clinical tests that can be used to help
characterize and stratify the pathogenesis of PE in real time, to date unrealized key objectives for
obstetric care.
344

Acknowledgements. We thank N. Aghaeepour and I. Maric from Stanford University for helpful discussion and data analysis suggestions, the many researchers and clinicians affiliated with the March of Dimes Prematurity Research Center at Stanford University for insightful feedback after oral presentations, and the participants in this study for their invaluable contribution.

Funding. This work was supported by the Chan Zuckerberg Biohub and the March of Dimes Foundation. M.N.M. is supported by the Stanford Bio-X Bowes Fellowship. S.K.V. is supported by a NSF Graduate Research Fellowship (Grant # DGE 1656518), the Benchmark Stanford Graduate Fellowship, and the Stanford ChEM-H Chemistry Biology Interface (CBI) training program. V.D.W. is supported by the H&H Evergreen Fund.

Author contributions. M.N.M., G.M.S., D.K.S., and S.R.Q. conceptualized and designed this study. M.L.D., V.D.W., G.M.S., and D.K.S. designed the cohort study at Lucile Packard Children's Hospital. R.J.W., A.A.C., and C.C.Q. collected and processed whole blood samples and corresponding sample and participant metadata. GAPPS oversaw, collected, and processed whole blood samples and corresponding sample and participant metadata at GAPPS. M.N.M. developed experimental protocols for cfRNA extraction and data generation and processed all samples from cfRNA extraction up to and including RT-qPCR and library generation for RNA sequencing. R.V.S., M.T., A.D., H.M., and N.F.N. developed and executed experimental protocols for RNA sequencing and computational protocols for raw sequencing data transfer. S.K.V. developed computational methods to define genes as cell-type and tissue specific in the context of the whole body. M.N.M and S.K.V. designed the analyses to characterize tissue and cell type contributions. M.N.M. conceptualized and developed computational analyses, analyzed the data, and wrote the initial manuscript draft in collaboration with S.R.Q.. All authors contributed to the writing and editing the manuscript.

Competing interests. The authors declare the following competing interests: M.N.M., S.K.V., G.M.S., D.K.S., and S.R.Q. are inventors on a patent application submitted by the Chan Zuckerberg Biohub and Stanford University that covers noninvasive early prediction of preeclampsia and monitoring maternal organ health over pregnancy. S.R.Q. is a founder, consultant, and shareholder of Mirvie. M.N.M. is also a shareholder of Mirvie.

Materials & methods

Clinical study design

Discovery and Validation 1 were collected as part of a longitudinal, prospective study. We enrolled pregnant mothers (aged 18 years or older) receiving routine antenatal care on or prior to 12 weeks of gestation at Lucile Packard Children's Hospital at Stanford University, following study review and approval by the Institutional Review Board (IRB) at Stanford University (#21956). All signed informed consent prior to enrollment. Whole blood samples for plasma isolation were then collected at three distinct timepoints during their pregnancy course and once (or twice for 2 individuals) post-partum.

Validation 2 was collected as part of the Global Alliance to Prevent Preterm and Stillbirth (GAPPS) at several, independent sites. Samples were processed and sequenced at Stanford under the same IRB as above (#21956). All signed informed consent prior to enrollment. Whole blood

391 samples for plasma isolation were collected at a single time point (or 2 timepoints in the case of 2
392 individuals with PE) prior to or at 16 weeks of gestation.
393
For all three cohorts, we ensured that all included individuals did not have chronic hypertension
or gestational diabetes. Mothers were defined as having PE based upon current American College
of Obstetrics and Gynecology (ACOG) guidelines (see below). Mothers were defined as controls
if they had uncomplicated term pregnancies and either normal spontaneous vaginal or caesarean
deliveries. For mothers who developed PE, all antenatal samples included in this study were
collected prior to clinical diagnosis.
400
401 We tested for within cohort (NT vs PE) and across cohort differences in demographic variables
402 using a chi-squared test and ANOVA for categorical and continuous variables respectively. We
403 then applied Bonferroni correction and reported any differences as significant if adjusted $p \leq 0.05$.
404
405 **Definition of PE**
406 PE was defined per the ACOG guidelines [27] based on two diagnostic criteria: 1) new-onset
407 hypertension developing on or after 20 weeks of gestation and 2) new-onset proteinuria or in its
408 absence, thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or
409 cerebral or visual disturbances.
410
New-onset hypertension was defined when the systolic and/or diastolic blood were at least 140 or
90 mmHg, respectively, on at least 2 separate occasions between 4 hours and 1 week apart.
Proteinuria was defined when either 300 mg protein was present within a 24-hour urine collection
or an individual urine sample contained a protein/creatinine ratio of 0.3 mg/dL, or if these were
not available, a random urine specimen had more than 1 mg protein as measured by dipstick.
Thrombocytopenia, impaired liver function, and renal insufficiency were defined as a platelet
count of $< 100,000/\mu L$, liver transaminases $\geq 2x$ of normal, and serum creatinine > 1.1 mg/dL,
respectively.
419
Symptoms were defined as severe per the ACOG guidelines. Specifically, PE is defined as severe
if any of the following symptoms were present and diagnosed as described above: new-onset
hypertension with systolic and/or diastolic blood pressure of at least 160 or 110 mmHg
respectively, thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema,
new-onset headache unresponsive to medication and unaccounted for otherwise, or visual
disturbances.
426
427 Finally, a pregnant mother was considered to have early-onset PE if onset occurred before 34
428 weeks of gestation and late onset thereafter.
429
Sample preparation
Plasma processing
At Lucile Packard Children's Hospital, blood samples were collected in either EDTA-coated (Cat
No 368661, Becton-Dickinson) or Streck cfRNA BCT (Cat No 218976, Streck) tubes at ≤ 12, 13–
20, and ≥ 23 weeks of gestation, and post-partum for each participant. Within 30 minutes, tubes
were then centrifuged at 1600g for 30 minutes at room temperature. Plasma was transferred to 2-
mL microfuge tubes and centrifuged at 13000g for another 10 minutes in a microfuge. One

milliliter aliquots were then transferred to 2-mL Sarstedt screw cap microtubes (Cat No 50809242,
Fisher Scientific) and stored at -80˚C until analysis.
439
At GAPPS, blood samples were collected in EDTA-coated tubes at ≤16 weeks of gestation from
a network of collection sites including Yakima Valley Memorial Hospital, Swedish Medical
Center, and the University of Washington Medical Center. Per Standard Operating Procedure
(SOP), tubes were then centrifuged within 2 hours of collection at 2500RPM for 10 minutes at
room temperature in a swinging bucket rotor. Plasma was transferred to 2-mL cryovials in at most
1 mL aliquots and stored at -80˚C until analysis. Sample volume was also recorded.
446
cfRNA isolation
In 96-sample batches, cfRNA from 1-mL plasma samples was extracted in a semi-automated
fashion using the Opentrons 1.0 system and Norgen Plasma/Serum Circulating and Exosomal
RNA Purification 96-Well Kit (Slurry Format) (Cat No 29500, Norgen). Samples were
subsequently treated with Baseline-ZERO DNAse (Cat No DB0715K, Lucigen) for 20 minutes at
37˚C. DNAse-treated cfRNA was then cleaned and concentrated into 12 µL using Zymo RNA
Clean and Concentrator-96 kits (Cat No R1080).
454
455 Following cfRNA extraction from plasma samples, isolated RNA concentrations were estimated
456 for a randomly selected 11 samples per batch using Bioanalyzer RNA 6000 Pico Kit (Cat No 5067-
457 1513, Agilent) per manufacturer instructions.
458
Sequencing library preparation
cfRNA sequencing libraries were prepared with SMARTer Stranded Total RNAseq Kit v2 - Pico
Input Mammalian Components (Cat No 634419, Takara) from 4 µL of eluted cfRNA according to
the manufacturer's instructions. Samples were barcoded using SMARTer RNA Unique Dual Index
Kit – 96U Set A (Cat No 634452, Takara), and then pooled in an equimolar fashion and sequenced
on Illumina's NovaSeq platform (2x75 bp) to a mean depth of 54, 33, and 38 million reads per
sample for Discovery, Validation 1, and Validation 2 cohorts, respectively. Some samples (12, 61,
0 for Discovery, Validation 1, and Validation 2 cohorts) were not sequenced due to failed library
preparation.
468
Sequencing data analysis
Bioinformatic processing
For each sample, raw sequencing reads were trimmed using Trimmomatic (v 0.36) and then
mapped to the human reference genome (hg38) with STAR (v 2.7.3a). Duplicate reads were then
removed by GATK's (v 4.1.1) MarkDuplicates tool. Finally, mapped reads were sorted and
quantified using htseq-count (v 0.11.1) generating a counts table (genes x samples). Read statistics
were estimated using FastQC (v 0.11.8).
476
477 Across samples, the bioinformatic pipeline was managed using Snakemake (v 5.8.1). Read and
478 tool performance statistics were aggregated across samples and steps using MultiQC (v 1.7).
479 Following sample quality and gene filtering, all gene counts were adjusted to $\log_2$-transformed
480 counts per million reads (CPM) with trimmed mean of M values (TMM) normalization [61].
481
Sample quality filtering

For every sequenced sample, we estimated three quality parameters as previously described [62,63].
To estimate RNA degradation in each sample, we first counted the number of reads per exon and
then annotated each exon with its corresponding gene ID and exon number using htseq-count.
Using these annotations, we measured the frequency of genes for which all reads mapped
exclusively to the 3' most exon as compared to the total number of genes detected. RNA
degradation for a given sample can then be approximated as the fraction of genes where all reads
mapped to the 3' most exon. To estimate the number of reads that mapped to genes, we summed
counts for all genes per sample using the counts table generated from bioinformatic processing
above. To estimate DNA contamination, we quantified the ratio of reads that mapped to intronic
as compared to exonic regions of the genome.
493
494 After measuring these three metrics across nearly 700 samples, we empirically estimated RNA
495 degradation and DNA contamination's 95th percentile bound. We considered any given sample an
496 outlier, low quality sample if its value for at least one of these metrics was greater than or equal to
497 the 95th percentile bound or if no reads were assigned to genes.
498
Once values for each metric were estimated across the entire dataset, we visualized: (1) whether
low-quality samples clustered separately using hierarchical clustering (average linkage, Euclidean
distance metric) and (2) whether sample quality drove variance in gene measurements using
principal component analysis (PCA). These analyses were performed in Python (v 3.6) using
Scikit-learn for PCA (v 0.23.2), Scipy for hierarchical clustering (v 1.5.1), and nheatmap for
heatmap and clustering visualization (v 0.1.4).
505
506 ***Gene filtering***
507 We performed filtering to identify well-detected genes across the entire cohort. Specifically, we
508 used a basic cutoff that required a given gene be detected at a level of at least 0.5 CPM in at least
509 75% of discovery samples after removing outlier samples. Following this step, we retain 7,160
510 genes for DE analysis.
511
Differential expression analysis
Differential expression analysis was performed in R using Limma (v 3.38.3). To identify gene
changes associated with PE across gestation and post-partum, we used a mixed-effects model. We
performed DE using two design matrices: (1) Examine the interaction between time to PE onset
or delivery for NT and PE symptoms (i.e., PE with or without severe symptoms) and (2) Examine
the interaction between time to PE onset or delivery for NT and PE broadly. In both design
matrices, we included time to PE onset or delivery for NT (continuous variable), whether a sample
was collected post-partum (binary variable), the interaction between time and PE symptoms for
(1) or PE for (2), the interaction between whether a sample is post-partum and PE symptoms for
(1) and PE for (2), and 7-8 confounding factors.
522
In (1), we defined PE symptoms categorially using 3 levels - NT, PE without severe symptoms,
PE with severe symptoms). In (2), we defined whether a sample was PE using a binary, indicator
variable (0 = NT, 1 = PE). The 7-8 confounding variables included were maternal race (categorial
variable), maternal ethnicity (binary variable), fetal sex (binary variable), maternal pre-pregnancy
BMI group (categorical variable), maternal age (continuous variable, only included in design 1),
and sequencing batch (categorical variable). We defined time to PE onset or delivery as the

difference between gestational age at onset or delivery and gestational age at sample collection.
We defined BMI group as follows: Obese (BMI ≥ 30), Overweight (25 ≤ BMI < 30), Healthy (18.5
≤ BMI < 25), Underweight (BMI < 18.5). We chose to model time to PE onset or delivery as a
continuous variable, specifically a natural cubic spline with 4 degrees of freedom to account for
the range across which samples were collected (1–3 months per collection period). We also
blocked for participant identity (categorical variable), modeling it as a random effect to account
for auto-correlation between samples from the same person.
536
Per the Limma-Voom guide, to account for sample auto-correlation over time, we ran the function
voomWithQualityWeights twice. We first ran it without any blocking on participant identity, and
used this base estimation to approximate sample auto-correlation based on participant identity
using the function duplicateCorrelation. After estimating correlation, voomWithQualityWeights
was run again, this time blocking for participant identity and including the estimated auto-
correlation level. A linear model was then fit for each gene using lmFit and differential expression
statistics were approximated using Empirical Bayes (eBayes) methods. For comparing PE with vs
without severe symptoms, we contrasted the relevant coefficients (makeContrasts) and then
applied Empirical Bayes as opposed to directly after lmFit.
546
DEGs were then identified using the relevant design matrix coefficients and the function, topTable,
with Benjamini-Hochberg multiple hypothesis correction at a significance level of 0.05. For design
1, we identified DEGs related to 3 comparisons: PE without severe symptoms vs NT (1759 DEGs),
severe PE vs NT (1198 DEGs), and PE with vs without severe symptoms (503 DEGs). We find
544 genes in common for PE without and with severe symptoms vs NT. These 544 DEGs were
explored in Figure 2 and the related main text. For design 2, we identified DEGs related to PE vs
NT alone (330 DEGs), which we used as the initial gene set for building a logistic regression model
(see Supplementary Note 2). Finally, we removed the effect of sequencing batch alone on
estimated logCPM values with TMM normalization for the Discovery cohort using the limma-
voom function, removeBatchEffect.
557

log(Fold change) and CV estimation
We define $\log_2$-transformed fold-change (logFC) as the difference between the median gene level
(logCPM, see Bioinformatic processing section above) between PE and NT samples for a given
sample collection period (i.e., ≤12, 13–20, and ≥23 weeks of gestation, or post-partum). In the case
where a given person had multiple samples included into a specific collection period, we only used
the values associated with the first collected sample to avoid artificially reducing within-group (PE
or NT) variance due to auto-correlation among samples from the same person.
565
We then quantified the relative dispersion around the estimated logFC for each gene using an
approximation for CV. Specifically, we consider CV to be the ratio between an error bound, ∂, and
the estimated logFC. We defined the error bound, ∂, as the one-sided error bound associated with
the lower (or upper in the case of negative logFC values) 95% CI as estimated by bootstrapping.
This definition of ∂ as a one-sided bound that approaches 0 (equivalent to no FC) allowed us to
explore how confident we could be in an estimated logFC. For instance, a CV = 1 would indicate
that at the boundary of proposed values, the logFC for a given gene becomes effectively 0.
Similarly, a CV > 1 would indicate even less confidence in a proposed average logFC and indicate

that at the boundary, the estimated logFC changes signs (i.e., a negative logFC becomes a positive
one or vice versa).
576
Hierarchical clustering analysis

For each sample collection period, hierarchical clustering was performed using differentially
expressed genes with an |logFC| ≥ 1 and CV < 0.5 or 0.4 in the case of the 13–20 weeks of gestation
time point so that the number of genes used did not exceed the number of samples. For each gene
that passed these thresholds, we calculated a z-score across all samples (at most 1 per subject, the
earliest collected sample in a given group) in each sample collection period using the function
StandardScaler in Scikit-learn (v 0.23.2), Average linkage hierarchical clustering with a Euclidean
distance metric was then performed for both rows (gene z-scores) and columns (samples in same
collection group) for a given matrix in Python using Scipy (v 1.5.1). Clustering and corresponding
heatmaps were visualized using nheatmap (v 0.1.4).
587
Longitudinal dynamics analysis

To group gene changes by longitudinal behavior, we performed k-means clustering on a matrix
where each row was a differentially expressed gene and each column was the estimated logFC for
a given sample collection period (N genes x 4 timepoints). We measured the sum of squared
distances for every 'k' between 1 and 16 (4^2) where 16 represents the maximum possible k (4
timepoints with 2 possibilities each, logFC > 0 or logFC < 0). We then identified the optimal k
clusters by using the well-established elbow method to identify the smallest 'k' that best explained
the data, visually described as the elbow (or knee) of a convex plot like that for the sum of squared
distances vs k (Fig S4A,C). To do so, we either visually inspected and identified the elbow (Fig
2D) or used the function KneeLocator as implemented in the package Kneed (v 0.7.0) (Fig 4A).
We used visual inspection for Fig 2D as we observed that given two k-values (e.g., k = 2,3) with
similar sum of squared distances, KneeLocator would choose the larger value whereas we
preferred a simpler model. Having identified the optimal number of clusters, 'k', we labeled every
differentially expressed gene with its assigned cluster and visualized average behavior (median)
and the 95% CI (bootstrapped using 1000 iterations) per cluster using Seaborn line plot (v 0.10.0).
603
604 To confirm that the identified patterns were not spurious (i.e., an artifact of the k-means clustering
605 algorithm), we permuted the data columns (logFC per timepoint) for each gene thereby scrambling
606 any time-related structure while preserving its overall distribution. We then visualized the result
607 using Seaborn line plot as described above. Following permutation, we observed no longitudinal
608 patterns, which were instead replaced by nearly flat, uninformative trends (Fig S4B,D).
609
Correlation analysis

To verify DEGs identified in the Discovery cohort, we compared logFCs for the Discovery as
compared to both Validation 1 and Validation 2 cohorts. We calculated the percentage of genes
for which the logFC had the same sign across cohorts (i.e., both positive or both negative) and the
spearman correlation using the function scipy.stats.spearmanr. We did not calculate logFCs for
DEGs at ≤12 weeks of gestation in Validation 1 because of small sample numbers (3 PE samples
prior to 12 weeks).
617
We also sought to compare whether symptom severity (without or with severe) correlated with
logFC magnitude for 544 DEGs identified as common to all PE in design 1. To do so, we

calculated the slope of a best-fit line where x and y were defined as logFCs for PE without (x) and
with (y) severe features vs NT. We would expect a slope > 1 and < 1 if logFC magnitudes for PE
with as compared to without severe symptoms were larger or smaller on average respectively.
Similarly, a slope = 1 would reflect that symptom severity did not correlate with logFC magnitude
for the 544 DEGs tested.

Finally, to confirm that the identified correlations were significant, we permuted the data columns
(logFC per cohort) for each gene thereby scrambling any structure while preserving its overall
distribution. We then calculated the same statistics. Following permutation, we observe about 50-
55% logFC agreement, as expected at random, a spearman correlation of 0, and slope of 0.

Defining cell-type and tissue-specific gene profiles
Cell-type and tissue specific gene profiles were all identified as previously described [44]. We also
briefly summarize this method below.

On the tissue level, for genes and tissues (and some blood and immune cell types) measured in the
Human Protein Atlas (HPA, v19)[55], we calculated a Gini index per gene as a measure of tissue
specificity. As a measure of inequality, Gini index values closer to 1 represent genes that are tissue
specific. We defined a given gene Y as specific to tissue X if $Gini(Y) \geq 0.6$ and max expression
for Y is in tissue X. Although the aforementioned method identifies fairly tissue specific genes, it
is possible to have a gene Y where $Gini(Y) \geq 0.6$ and the gene is expressed in more than 1 tissue
(e.g., enrichment in placenta and muscle). To this end, when tracking cell-type and tissue
trajectories over gestation (e.g., Fig 4B), where the specificity of a given gene profile is especially
important, we imposed a further constraint to ensure that any gene signal only reflects the named
tissue (e.g., any gene named placenta specific is specific to the placenta alone). Specifically, we
required that genes be annotated by HPA as 'Tissue enriched' or 'Tissue enhanced' and term this
reference, HPA strict.

On the cell-type level, we augmented Tabula Sapiens v1.0 (TSP) with cell types from missing
(e.g., placenta, brain), incompletely described tissues (e.g., kidney), or additional annotations (e.g.,
liver) known to be important in PE. We term this augmented reference TSP+. For genes and cell
types measured in Tabula Sapiens v1.0 (TSP), we defined a given gene Y as specific to cell-type
X if $Gini(Y) \geq 0.8$ and max mean expression for Y is in cell-type X. We combined annotations for
all neutrophil and endothelial subtypes as these were based on manifold clustering and it was
unclear if the subtypes were truly distinct enough to be distinguished at a whole-body level for our
purposes. For genes and cell types described in individual tissue single-cell atlases, we required
that a gene be differentially expressed in the specific single cell atlases and tissue specific per the
HPA $(Gini \geq 0.6)$. The following single cell atlases were used for each organ: 1) Placenta [64,65] 2)
Liver [66] 3) Kidney [67] 4) Heart [68] 5) Brain [69].

For TSP+, we then took the union of TSP and individual atlas gene annotations. A small number
of genes had conflicting double annotations in TSP as compared to at most one individual tissue
single cell atlas. In these rare instances, which most often occurred for genes related to cell-types
missing in TSP (e.g., placental or brain cell-types), we preferred the individual single-cell atlas
label to TSP.

Determining cell type and tissue of origin

We determined whether a given cell-type or tissue was enriched in PE by comparing PE DEGs with cell-type and tissue gene profiles using a hypergeometric test. For every tissue (HPA) or cell-type (TSP+) with at least 2 DEGs specific to it, we performed the following. First, we defined a hypergeometric distribution (scipy.stats.hypergeom, (v 1.5.1)) with the following parameters where category refers to tissue when using HPA and cell-type when using TSP+: M = Number of genes specific to any category, n = Number of genes specific to this category, N = number of DEGs in this k-means longitudinal cluster specific to this category. Next, we estimated a p-value using the survival function (1-CDF) for the specified distribution. Specifically, a p-value is defined as the cumulative probability, prob(X>(n_DEGs_specific_to_this_category–1)), that the distribution takes a value greater than the number of DEGS specific to this category – 1. Finally, once we estimated a p-value for every cell-type (TSP+) or tissue (HPA) identified in each DEG k-means longitudinal cluster, we adjusted for multiple hypotheses using Benjamini-Hochberg and a significance threshold of 0.05.

Defining relative signature score per cell type or tissue

We define a signature score as the sum of logCPM values over all genes in a given tissue or cell-type gene profile. We required that a cell type or tissue gene profile have at least 5 specified genes to be considered for signature scoring in cfRNA. Genes were defined as specific to a given tissue based on the reference, HPA strict, and to a given cell type, based on the reference TSP+ (see "Defining cell-type and tissue-specific genes" for details).

To account for our prior observation that baseline cfRNA levels vary per subject – the consequence of biological and technical (e.g., sample processing) factors, we chose to calculate relative as opposed to absolute signature scores. For each subject for which the post-partum sample passed sample QC (see "Sample quality filtering" for details), we estimated a relative signature score defined as the difference between the signature score at a given gestational time point and the post-partum sample. For both Discovery and Validation 1, 49 NT and 24 PE subjects had a post-partum sample that survived sample QC. After normalization, all samples at post-partum had a similar baseline (0). We note that one can define a relative signature score based on any sampled time point for a given person. We chose the post-partum sample because we were interested in tracking maternal organ health over gestation.

Finally, we scaled (i.e., z-score) the relative signature scores for a given cell type or tissue by dividing by the interquartile range, a robust alternative to standard deviation, using the sklearn.preprocessing class, RobustScaler. This accounted for differing gene profile lengths and gene expression levels, and allowed us to compare both different cell-type and tissue contributions and case groups per cell-type or tissue.

Having defined a relative signature score per cell-type and tissue, we visualized average behavior (median) and the 75% CI, a non-parametric estimation of standard deviation, (bootstrapped relative signature score per case group and timepoint using 1000 iterations) using Seaborn line plot (v 0.10.0).

Functional enrichment *analysis*

Functional enrichment analysis was performed using the tool, GProfiler (v1.0.0) for the following data sources, Gene ontology: biological processes and cellular compartments (GO:BP, GO:CC,

712 released 2021-05-01), Reactome (REAC, released 2021-05-07), and Kyoto Encyclopedia of Genes
713 and Genomes (KEGG, released 2021-05-03). To identify GO terms, we excluded electronic GO
714 annotations (IEA) and used a custom background of only the 7160 genes that were included in DE.
715 We then performed the recommended multiple hypothesis correction (g:SCS) with an experiment
716 wide significance threshold of a = 0.05 [70].
717
718 *Logistic regression feature selection and training*
719 To build a robust classifier that can identify mothers at risk of PE at or before 16 weeks of
720 gestation, we first pre-selected features using the set of 330 DEGs when contrasting PE vs NT (see
721 design 2 in "Differential expression analysis" and Supplementary Note 2) as a starting point.
722
We normalized gene measurements using a series of steps. First, to correct for batch effect, where
we define batch as a set of samples processed at the same time by a distinct group (e.g., Discovery
cohort = batch, Del Vecchio and colleagues' cohort = batch), we centered the data by subtracting
the median logCPM per gene for a given cohort. Next, we scaled gene values for each cohort using
its corresponding interquartile range in the Discovery cohort. Finally, to account for sampling
differences across sample, we used an approach similar to when analyzing RT-qPCR data, and
normalized data using multiple internal control (i.e., housekeeping) genes. On a per sample basis,
we subtracted the median, normalized logCPM value (centered and scaled) for all internal control
genes, which we define as 66 genes for which the measured value did not change across PE vs NT
comparisons (All genes with adjusted p-value > 0.99 for PE vs NT, Design 2). When calculating
the median value for all internal control genes, we excluded any 0 logCPM values as these were
likely the consequence of technical dropout.
735
736 Model training then used the Discovery cohort alone split into 80% for hyperparameter tuning and
737 20% for model selection and consisted of two stages – further feature pre-selection based on two
738 metrics followed by the construction of a logistic regression model with an elastic net penalty.
739 Using a split Discovery cohort for training mitigated overfitting even though all Discovery samples
740 were used for differential expression, which defined the initial feature set.
741
For feature pre-selection, we calculated logFC values using the 80% Discovery split for all 330
genes for PE vs NT. We focused on two practical metrics measured across the 80% split of
Discovery samples collected on or before 16 weeks of gestation: gene change size (|logFC|) and
gene change stability (CV). All model hyperparameters were then tuned using AUROC as the
outcome metric and 5-fold cross validation. Next, we selected the best model including tuned
feature pre-selection cutoffs again using AUROC. Specifically, we calculated an AUROC score
for both the 80% and 20% Discovery splits separately, and the selected model achieved the best
score on both splits
750
Finally, we tuned the probability threshold, P, at which a sample is labeled as at risk of PE if
prob(PE) $\geq$ P using the entire Discovery cohort. To do so, we constructed a receiver operator
characteristic curve (ROC) and calculated the false positive rate (FPR) and true positive rate (TPR)
at different thresholds, P_i,. We identified the threshold, P_i, at which FPR=10%, and round to the
nearest 5 (e.g., 0.37 would become 0.35). This yielded a tuned threshold of P = 0.35. All
classifications as negative or positive were then made based on this threshold.
757

758   To understand the importance of each gene feature, we trained a separate logistic regression model
759   for a subset of all possible feature subset (307 combinations out of a total of 262143 for 1–17
760   genes). No feature pre-selection was performed for this sub-analysis. All model hyperparameters
761   were tuned as previously described. We defined a gene subset as weakly predictive if the model
762   yielded an AUROC > 0.5 on the test set (Validation 2).
763
764   In all cases, performance metrics were assessed as described below (see next section) and used
765   Scikit-learn (v 0.23.2),
766
Performance metric analysis
Model performance was assessed using several statistics including sensitivity, specificity, PPV,
NPV, and AUROC. Given a 2x2 confusion matrix where rows 1and 2 represent true negatives and
positives and columns 1 and 2 represent negative and positive predictions respectively, we can
define the value in row 1, column 1 as true negatives (TN), row 1, column 2 as false positives (FP),
row 2, column 1 as false negatives (FN), and row 2, column 2 as true positives (TP). We can then
define the following proportions: (1) Sensitivity = TP / (TP + FN) (2) Specificity = TN / (TN +
FP) (3) PPV = TP / (TP + FP) (4) NPV = TN / (TN + FN). For each proportion, we calculated 90%
CIs using Jeffrey's interval [71] and the function, proportion_confint, from
statsmodels.stats.proportion. We also approximated AUC and its corresponding 90% CI using the
Scikit-learn function, roc_auc_score, and the binormal approximation respectively.
778
779   **Statistical analyses**
780   All p-values reported herein were calculated using the non-parametric Mann-Whitney rank test
781   unless otherwise stated. One-sided tests were performed where required based on the hypothesis
782   tested.
783
784   **Code/data availability**
785   All computational analyses were performed using Python 3.6 or R 3.5, and will be available on
786   Github. Raw and processed sequencing data will be deposited with the SRA and GEO,
787   respectively.
788

Figure 1. Comparing sample, maternal, and pregnancy characteristics for NT and PE groups across all cohorts. Panels illustrate matched sample collection time (weeks) in (**A**), maternal characteristics (Top to bottom: BMI, age, and gravidity) in (**B**), matched gestational age at PE onset regardless of PE symptom severity in (**C**), and gestational age at delivery in (**D**) for Discovery, Validation 1, and Validation 2 cohorts. For (**A**), schematic depicts blood sampling across gestation and plasma isolation. X-axis represents gestational age during pregnancy and time post-delivery (weeks) thereafter (ns = not significant, * $p < 0.05$ ** $\leq 10^{-7}$). BMI data is not available for Validation 2.

Figure 2. Before 20 weeks of gestation, changes in the cfRNA transcriptome segregate PE and NT samples and are enriched for neuromuscular, endothelial and immune cell types and tissues. (**A**) Distribution of log(Fold change) with dashed lines at log(Fold change) = ± 1 (**B**) At ≤12 and between 13–20 weeks of gestation, a subset of differentially expressed genes can separate PE and NT samples despite differences in symptom severity, PE onset subtype, and gestational age (GA) at delivery. (**C**) Comparison of log(Fold change) for DEGs between Discovery (x-axis) and Validation 2 (y-axis) reveals excellent agreement: 92%, and 94% of genes had the same logFC sign with a spearman correlation of 0.71 and 0.72 (p < 10⁻¹⁵) at ≤12 and 13–20 weeks of gestation, respectively. (**D**) Across gestation, differentially expressed genes for PE as compared to NT can be described by 2 longitudinal trends: Increased in PE over gestation in orange and Decreased in PE over gestation in dark blue as revealed by k-means clustering. (**E**) Approximately 13% of DEGs are tissue- or cell-type specific when compared with the Human Protein Atlas (HPA) and an augmented Tabula Sapiens (TSP+) atlas.

Figure 3. A subset of cfRNA changes can predict risk of PE early in gestation (**A**) Classifier performance as quantified by ROC for samples collected in early gestation between 5–16 weeks. For each cohort, including 3 validation cohorts of which Validation 2 and Del Vecchio are independent, the legend states the AUROC and the corresponding 90% CI in square brackets. (**B**) Prediction of PE incorporates cfRNA levels for 18 genes for which normalized centered $\log_2$(Fold change) trends hold across discovery, Validation 1, Validation 2, and Del Vecchio cohorts as confirmed using univariate analysis (*p $\leq$ 0.05, **p $\leq$ 0.01, ***p $\leq$ 0.005; one-sided Mann-Whitney U-Test with Benjamini-Hochberg correction). For box-plots, center line, box limits, whiskers, and outliers represent the median, upper and lower quartiles, 1.5x interquartile range, and any outliers outside that distribution respectively. Plot limits are -8 to 4 to better visualize the main distribution.

Figure 4. Changes in the cfRNA transcriptome reflect PE's multifactorial nature and pathogenesis over pregnancy prior to diagnosis. (**A**) Across gestation, differentially expressed genes for PE with as compared to without severe features (503 DEGs) can be described by 4 longitudinal trends as revealed by k-means clustering. Points indicate median per DEG cluster and shaded region indicates 95% CI. (**B**) Comparison of organ and cell-type changes over gestation for eight organ systems reflect the multifactorial nature of PE and provide a possible means to monitor maternal organ health (Top to bottom: Brain, immune, placenta and kidney, heart and endothelial-linked, liver and muscle). Points indicate median per sample group (NT in black, PE without severe features in yellow, PE with severe features in red) and shaded region indicates 75% CI.

Table 1. PE prediction performance metrics for samples collected early in gestation (between 5–16 weeks). Control and case sample numbers are reported as the total sample number and in parentheses, the number of samples misclassified. All other statistics including sensitivity specificity, PPV, NPV, and AUROC are reported as the estimated percentage followed by the 90% CI in square brackets. In Del Vecchio[1], the control group is defined as samples from any pregnant mother who did not develop PE including those with other underlying or pregnancy-related complications like chronic hypertension and gestational diabetes respectively. In Del Vecchio[2], the control group is defined as samples strictly from NT pregnant mothers who did not experience complications.

	Control (n)	Case (n)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUC
Discovery	61 (9)	24 (0)	100 [92-100]	85 [77-91]	73 [59-84]	100 [96-100]	0.99 [0.99-0.99]
Validation 1	35 (11)	8 (3)	75 [46-92]	56 [43-70]	28 [15-46]	91 [77-97]	0.71 [0.7-0.71]
Validation 2	61 (19)	28 (12)	56 [42-71]	69 [59-78]	46 [32-59]	78 [68-86]	0.72 [0.71-0.72]
Del Vecchio[1] (2020)	17 (0)	5 (2)	60 [26-87]	100 [89-100]	100 [56-100]	89 [74-97]	0.74 [0.73-0.74]
Del Vecchio[2] (2020)	8 (0)	5 (2)	60 [26-87]	100 [79-100]	100 [56-100]	80 [55-94]	0.80 [0.79-0.80]

849 **Supplementary text**
850

Supplementary note 1: Establishing quality metrics to identify sample outliers
Because cfRNA measurements can be noisy [31,72], we have previously developed and reported on
three quality metrics that can flag sequenced cfRNA samples with poor quality [62,63]. Specifically,
these metrics aim to quantify unusually high levels of RNA degradation and/or DNA
contamination by comparing a given sample's value for any of these metrics with what we expect
empirically. We defined reasonable expected values for each metric based on the 95th percentile
for ~700 previously sequenced samples across 3 cohorts.
858

We found that samples with outlier values for at least one of these metrics both clustered separately
and served as leverage points in PCA (Fig S1A-C). To avoid introducing unwanted bias, we
removed these low-quality samples from any further analysis. After removing outlier samples, we
reran PCA and noticed that some samples continued to serve as leverage points. We suspected that
this may be due to genes that were poorly detected and consequently performed further filtering to
identify well-detected genes across the entire cohort. Specifically, we used a basic cutoff that
required a given gene be detected at a level of at least 0.5 CPM reads in at least 75% of samples
after removing outlier samples. Following this step, we retain 7,160 genes for analysis. Upon
inspection, we find that visualization using PCA is no longer driven by leverage points.
868

Supplementary note 2: Selecting an initial feature set for machine learning
We first explored whether a common gene set could describe PE with or without severe features.
We observed that we could separate PE from NT samples (Fig 2) irrespective of symptom severity
and that PE with or without severe features as compared to NT had on average the same log FC
(Fig S2E). With this in mind, we reran differential expression to identify a core set of genes that
can distinguish PE (as a binary case group) from NT (See Design 2 in methods section "Differential
expression analysis" for more details). This identified 330 genes that we used as an initial feature
set for machine learning.

Fig S1. Samples with outlier values for at least one of QC metric cluster separately from most non-outlier samples. For Discovery (**A**), Validation 1 (**B**), and Validation 2 (**C**), hierarchical clustering (left) and PCA reveals that most outlier samples cluster with negative control (NC) samples (H2O) and separately from non-outlier samples. (**D, E**) Visualization of other QC metrics like the amount of cfRNA extracted (**D**) and the percent of reads that align uniquely to the human genome (**E**). For PCA in (**A-C**), sample outliers and poorly detected genes drive PCA and serve as leverage points. The top two principal components are visualized when performed using all samples and all genes (leftmost PCA) or only samples that pass QC metrics (middle PCA) reveals that certain samples can act as leverage points. Once sample outliers and lowly detected genes are removed from the cfRNA gene matrix (rightmost PCA), the top two principal components reflect natural variance in the data and are no longer driven by a few leverage points.

Fig S2. Across gestation prior to diagnosis, changes in the cfRNA transcriptome segregate PE and NT samples and reflect known PE biology. (**A**) Distribution of CVs with dashed line at CV = 1 for all DEGs between PE as compared to NT samples across gestation. (**B**) At ≥23 weeks of gestation and post-partum, in each sample collection period, a subset of DEGs can separate PE and NT samples despite differences in symptom severity, PE onset subtype, and gestational age (GA) at delivery. (**C**) Comparison of log(Fold change) for DEGs for PE as compared to NT between Discovery (x-axis) and Validation 1 (y-axis) reveals good agreement across gestation but not post-partum: 82%, 83%, and 60% of genes had the same logFC sign with a Spearman correlation of 0.67, 0.69, and 0.35 (p < 10^-15) at 13–20, ≥23 weeks, and post-partum, respectively. (**D**) The genes in each longitudinal trend group reflect known PE etiology as highlighted across four databases (GO biological processes, KEGG, the reactome, and GO cellular compartment). Some PE associated terms are emphasized in bold, colored text that corresponds to group color from Fig 2D (Dark blue and orange indicate decreased and increased in PE vs NT, respectively). (**E**) Comparison of log(Fold change) for DEGs for PE without severe features vs NT (x-axis) and PE with severe features vs NT in the Discovery cohort (y-axis) reveals good agreement along the y=x axis with a slope of 0.93, 1.03, 0.77, and 0.86 at ≤12 weeks, 13–20, ≥23 weeks, and post-partum, respectively.

Fig S3. Across gestation and prior to diagnosis, changes in the cfRNA transcriptome identified at one timepoint can moderately segregate PE and NT samples at other timepoints. DEGs with |logFC| ≥ 1 and CV < 0.5 or 0.4 for 13–20 weeks timepoint were identified at each timepoint across gestation. Each row visualizes how well a specific DEG subset from a given sample collection period can separate PE and NT samples in all other collection periods (columns). The number of genes identified per sample collection period is highlighted along the main diagonal.

Fig S4. K-means clustering reveals meaningful longitudinal patterns. The chosen k clusters (dashed line) comparing a performance metric, the sum of squared distances, and values of k for clustering of DEGs for PE vs NT related to Fig 2D in (**A**) and DEGsfor PE with vs without severe features related to Fig 4A in (**C**). Following permutation of the data matrix prior to k-means clustering, longitudinal changes over gestation are replaced by (**B**) 2 flat lines for clustering of logFC for PE vs NT and (**D**) 4 uninformative lines for clustering of logFC for PE with vs without severe features.

924
925

Fig S5. Examining the logisitic regression model used to predict risk of PE early in gestation
(**A**) Comparison of gestational age at sample collection (weeks) for incorrectly predicted (yellow)
or correctly predicted (green) samples across NT and PE groups in Discovery, Validation 1,
Validation 2, and Del Vecchio shows that incorrectly predicted PE samples (false negatives) are
collected at later gestational ages. (**B**) Estimated probability of PE as outputted by logistic
regression for both PE and NT samples shows that the model is well-calibrated across most
predictions. Dashed line at 0.35 indicates classifier cutoff where probability(PE) $\geq$ 0.35 constitutes
a sample predicted as PE. (**C**) Logistic regression models trained on subsets of 1–18 genes of the
initial 18 genes can moderately predict future PE onset in Validation 2 cohort with improving
performance as subset size increases and as characterized by PPV, NPV, sensitivity, specificity,
and AUROC (left to right).

Table S1. Participant, pregnancy, and PE characteristics across both Discovery and
Validation cohorts. Maternal age and BMI, gestational age (GA) at delivery, fetal weight, and
GA at PE onset are reported mean ± SD. All other values are reported as percentages with the
corresponding count in parentheses. Small for GA (SGA) was defined as an infant with a
birthweight below the 10th centile for their GA at delivery. Pre-pregnancy BMI was not available
for individuals in Validation 2 cohort. AI/AN indicates American Indians and Alaska Natives.
*adjusted p ≤ 0.05, chi-squared (categorical) or ANOVA (continuous) test comparing all cohorts
‡ adjusted p ≤ 0.05, chi-squared (categorical) or ANOVA (continuous) test comparing PE and NT
within each cohort
† denotes that missing values were omitted from reported values for a given feature.

Maternal pre-pregnancy characteristics

		Age, years	BMI, kg/m^2	Nulliparous, % (n) *	Smoker, % (n)	History of preterm birth, % (n) *	History of PE, % (n)
Discovery	NT	32 ± 5	23 ± 3 †,‡	31 (15)	2 (1)	16 (8)	2 (1)
	PE	31 ± 6	30 ± 8 ‡	38 (9)	0 (0)	25 (6)	17 (4)
Validation 1	NT	31 ± 5	25 ± 6 †	28 (9)	3 (1)	12 (4)	9 (3)
	PE	34 ± 5	26 ± 4	29 (2)	0 (0)	29 (2)	29 (2)
Validation 2	NT	30 ± 5	NA	0 (0)	5 (3)	0 (0) ‡	0 (0)
	PE	32 ± 6	NA	0 (0)	0 (0)	50 (13) ‡	12 (3)

Maternal ethnicity/race

		Ethnicity *	Race, % (n) *					
		Hispanic	White	AI/AN	Black	Asian	Other	Unknown
Discovery	NT	22 (11)	73 (36)	0 (0)	4 (2)	20 (10)	2 (1)	0 (0)
	PE	42 (10)	50 (12)	0 (0)	4 (1)	25 (6)	0 (0)	21 (5)
Validation 1	NT	34 (11)	72 (23)	0 (0)	6 (2)	16 (5)	6 (2)	0 (0)
	PE	57 (4)	71 (5)	0 (0)	0 (0)	14 (1)	0 (0)	14 (1)
Validation 2	NT	8 (5)	59 (36)	23 (14)	5 (3)	8 (5)	0 (0)	5 (3)
	PE	4 (1)	62 (16)	23 (6)	4 (1)	4 (1)	0 (0)	4 (1)

Pregnancy characteristics

		GA at delivery, weeks *	Mode of delivery % vaginal (n) *	Multi-gestation, % (n)	Preterm delivery, % (n) *	Fetal sex, % male (n)	Fetal weight, kg *	SGA, % (n)
Discovery	NT	39 ± 1 ‡	76 (37)	0 (0)	0 ‡	53 (26)	3.4 ± 0.4 ‡	0 (0)
	PE	36 ± 3 ‡	46 (11)	12 (3)	38 (9) ‡	54 (13)	2.8 ± 0.7 ‡	4 (1)
Validation 1	NT	39 ± 1	56 (18)	3 (1)	0 (0)	53 (17)	3.4 ± 0.5 †	0 (0)
	PE	38 ± 1	57 (4)	0 (0)	14 (1)	71 (5)	3.4 ± 0.3	0 (0)
Validation 2	NT	39 ± 1 ‡	75 (46) ‡	0 (0)	0 (0) ‡	46 (28)	3.4 ± 0.4 ‡	0 (0)
	PE	37 ± 2 ‡	35 (9) ‡	8 (2)	42 (11) ‡	54 (14)	2.9 ± 0.7 ‡	8 (2)

PE characteristics

		GA at onset, weeks	Onset type, % early (n)	Symptom severity, % severe (n)
Discovery	PE	36 ± 4	25 (6)	54 (13)
Validation 1	PE	38 ± 2	0 (0)	43 (3)
Validation 2	PE	38 ± 2 †	12 (3) †	50 (13) †

949
950

951 **Table S2. Number of subjects with a given number of samples that passed QC for**
952 **Discovery and Validation 1 cohorts**

	Number of samples				
	1	**2**	**3**	**4**	**5**
Discovery	5	19	31	17	1
Validation 1	7	8	14	9	1

Table S3. Tissue, cell-types, and genes previously implicated in PE enriched in 544 DEGs
identified when comparing PE with or without severe features and NT pregnancies. For
every significantly enriched tissue or cell-type (adjusted p ≤ 0.05, Hypergeometric test with
Benjamini-Hochberg correction), assigned k-means cluster (i.e., Fig 2D), reference, adjusted p-
values, are reported from left to right. Finally, the rightmost column lists the gene names for all
DEGs that were labeled as specific to a given cell-type or tissue. The last row lists gene set
enrichment with dbPEC, a PE specific database of genes.

K-means cluster	Specific to	Reference	Adjusted p-value	DEGs specific to cell-type or tissue
1, Decreased in PE	granulocytes	HPA	0.00026	ICAM3, PTPN6,SNX20, VNN2, LIMD2
	lymph node	HPA	0.013	CYTIP, CD48
	T-cells	HPA	0.02	TBC1D10C, TRAF3IP3
2, Increased in PE	platelet	TSP+	2.5×10^{-33}	GP9, SEPT5, AQP10, TREML1, CMTM5, GRAP2, RP11-142C4.6,BMP6, TUBB1, PTGS1, GP1BA,C6orf25, ITGA2B, PTCRA, ITGB3, RP3-370M22.8, BEND2, SEC14L5 ,ALOX12, F13A1,GP6, SLA2
	smooth muscle	HPA	0.00026	MYL9, PTGS1, MYLK, SYNM, FLNA
	total PBMC	HPA	0.00077	GP9, TREML1, TUBB1
	oligodendrocytes	TSP+	0.005	PCSK6, SH3TC2
	granulocytes	HPA	0.02	BIN2, GFI1B, ITGA2B, MTRNR2L12, NFE2
	excitatory neurons	TSP+	0.02	MTURN, NRGN
	mesenchymal stem cell	TSP+	0.03	COL6A3, NID1
	capillary aerocyte	TSP+	0.03	CLDN5, ESAM
	PE	dbPEC	0.006	CLU, ICAM3, TGFB1, IGF2, ADIPOR2, CDKN1A, GPX1, TGFBR1, RXRA, IFNGR2, JUN, PTGS1, F2R, NFKB1, GAPDH, SELP, NFKB2, ILK, GP9, ITGB3, CLDN5, ITGB1, ATP2A3, PDGFA, EGLN1, EGLN2, GP1BA, ACTB, VDR, CASP8

962 **Table S4. PE prediction relies on the cfRNA levels of 18 genes.** For every gene, symbol,
963 ENSEMBL ID, full name, odds ratio (OR) based on the logistic regression coefficient, and if
964 available, a subset of GO biological processes and molecular functions (if available) are reported
965 from left to right.

Gene	ENSEMBL	Name	Odds ratio	Biological process [GO]	Molecular function [GO]
CAMK2G	ENSG00000 148660	calcium/cal modulin dependent protein kinase II gamma	0.65	nervous system development, protein phosphorylation, regulation of neuron projection development, regulation of skeletal muscle adaptation, insulin secretion, cell differentiation	calcium-dependent protein serine/threonine phosphatase activity, identical protein binding, protein homodimerization activity,
DERA	ENSG00000 023697	deoxyribose-phosphate aldolase	1.07	pentose-phosphate shunt, deoxyribose phosphate catabolic process	deoxyribose-phosphate aldolase activity, protein binding
FAM46A	ENSG00000 112773	terminal nucleotidyl transferase 5A	0.91	mRNA stabilization, response to bacterium	RNA adenylyltransferase activity, protein binding, RNA binding
KIAA110 9	ENSG00000 138688	KIAA1109	0.89	synaptic vesicle endocytosis, regulation of epithelial cell differentiation, endosomal transport,	protein binding
LRRC58	ENSG00000 163428	leucine rich repeat containing 58	0.79		
MYLIP	ENSG00000 007944	myosin regulatory light chain interacting protein	0.94	nervous system development, regulation of low-density lipoprotein particle receptor catabolic process, ubiquitin-dependent protein catabolic process, negative regulation of neuron projection development	ubiquitin protein ligase activity, cytoskeletal protein binding, protein binding, metal ion binding, ubiquitin-protein transferase activity
NDUFV3	ENSG00000 160194	NADH:ubi quinone oxidoreduc tase subunit V3	0.66	mitochondrial electron transport, NADH to ubiquinone	NADH dehydrogenase (ubiquinone) activity, protein binding, RNA binding
NMRK1	ENSG00000 106733	nicotinami de riboside kinase 1	1.42	NAD metabolic process, phosphorylation, NAD biosynthetic process	ribosylnicotinamide kinase activity
PI4KA	ENSG00000 241973	phosphatid ylinositol 4-kinase alpha	0.9	multi-organism membrane organization, phosphorylation, viral replication complex formation and maintenance, signal transduction	kinase activity, phosphatidylinositol kinase activity, protein binding

PRTFDC1	ENSG00000 099256	phosphorib osyl transferase domain containing 1	1.32	guanine salvage, GMP catabolic process, purine ribonucleoside salvage	protein homodimerization activity, hypoxanthine phosphoribosyltransferase activity
PYGO2	ENSG00000 163348	pygopus family PHD finger 2	0.95	positive regulation of chromatin binding, developmental growth, lens development in camera-type eye, regulation of histone H3-K4 methylation, mammary gland development	chromatin binding, protein binding, metal ion binding, histone acetyltransferase regulator activity, histone binding
RNF149	ENSG00000 163162	ring finger protein 149	0.82	ubiquitin-dependent protein catabolic process, regulation of protein stability, protein ubiquitination,	ubiquitin protein ligase activity, metal ion binding
TFIP11	ENSG00000 100109	tuftelin interacting protein 11	0.9	biomineral tissue development, negative regulation of protein binding, spliceosomal complex disassembly, mRNA splicing, via spliceosome,	protein binding, nucleic acid binding
TRIM21	ENSG00000 132109	tripartite motif containing 21	0.88	negative regulation of protein deubiquitination, regulation of protein localization, regulation of gene expression, protein monoubiquitination,	zinc ion binding, transcription coactivator activity, identical protein binding
USB1	ENSG00000 103005	U6 snRNA biogenesis phosphodie sterase 1	0.85	U6 snRNA 3'-end processing, RNA splicing,	poly(U)-specific exoribonuclease activity
Y_RNA	ENSG00000 201412	Y RNA	1.85		
Y_RNA	ENSG00000 238912	Y RNA	1.08		
YWHAQ P5	ENSG00000 236564	YWHAQ pseudogene 5	1.09		

966
967

Table S5. Logistic regression models trained on some subsets of 1–18 genes of the initial 18 genes can predict future PE onset with nearly equivalent performance metrics. The associated performance metrics for each data split and some high-performing gene subsets is reported including sensitivity (Sens), specificity (Spec), PPV, NPV, and AUROC, which are reported as the estimated percentage. Only a few, illustrative examples are shown here.

Subset	Size	Validation 2				
		PPV	NPV	Sens	Spec	AUROC
DERA	1	48	84	75	62	0.76
TRIM21, PI4KA	2	44	76	54	69	0.71
TRIM21, Y_RNA, DERA	3	50	78	54	75	0.77
TRIM21, USB1, PYGO2, DERA	4	50	73	32	85	0.71
LRRC58, KIAA1109, MYLIP, USB1, NMRK1	5	48	78	54	74	0.70
Y_RNA, NDUFV3, KIAA1109, MYLIP, USB1, RNF149, PRTFDC1, PI4KA, NMRK1, YWHAQP5, Y_RNA	11	67	72	21	95	0.75

Table S6. Tissue and cell-types enriched in 503 DEGs identified when comparing PE with as compared to without severe features. For every significantly enriched tissue or cell-type (adjusted p ≤ 0.05, Hypergeometric test with Benjamini-Hochberg correction), assigned k-means cluster (i.e., Fig 4A), reference, adjusted p-values, are reported from left to right. Finally, the rightmost column lists the gene names for all DEGs that were labeled as specific to a given cell-type or tissue.

K-means cluster	Specific to	Reference	Adjusted p-value	DEGs specific to cell-type or tissue
1, Increased across gestation for severe PE	naive b cell	TSP+	0.0002	TCL1A,TNFRSF13C
	B-cells	HPA	0.002	FCMR,TCL1A
	neutrophil	TSP+	0.002	PADI4,MEFV,DOK3
	bone marrow	HPA	0.01	PADI4,DOK3
	endothelial cell	TSP+	0.04	PDE2A,VWF
2, Increased and then decreased in early and late gestation respectively for severe PE	granulocytes	HPA	0.0007	SELL,HK3,MXD1,ALPL
	neutrophil	TSP+	0.02	FCN1,HK3
4, Decreased across gestation for severe PE	thymus	HPA	0.01	CARMIL2,ARHGAP15

File S1. Table of 89 differentially expressed genes included in Fig 2B, S2B heatmaps. For every gene, the symbol, ENSEMBL ID, sample collection groups for which the gene passed cutoff thresholds, full name, ENSEMBL gene type, and a subset of GO biological processes and molecular functions are reported.

File S2. Table of all significant GO terms related to 544 DEGS for PE with or without severe features as compared with NT.

Bibliography

1. Centers for Disease Control and Prevention (CDC). Healthier mothers and babies. *MMWR Morb. Mortal. Wkly. Rep.* **48,** 849–858 (1999).

2. Basso, O. *et al.* Trends in fetal and infant survival following preeclampsia. *JAMA* **296,** 1357–1362 (2006).

3. Behrman, R. E., Butler, A. S. & Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Societal Costs of Preterm Birth. (2007).

4. Blencowe, H. *et al.* Born too soon: the global epidemiology of 15 million preterm births. *Reprod Health* **10 Suppl 1,** S2 (2013).

5. Stevens, W. *et al.* Short-term costs of preeclampsia to the United States health care system. *Am. J. Obstet. Gynecol.* **217,** 237–248.e16 (2017).

6. Beam, A. L. *et al.* Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008-2016. *J. Perinatol.* **40,** 1091–1099 (2020).

7. Say, L. *et al.* Global causes of maternal death: a WHO systematic analysis. *Lancet Glob. Health* **2,** e323-33 (2014).

8. Petersen, E. E. *et al.* Vital Signs: Pregnancy-Related Deaths, United States, 2011-2015, and Strategies for Prevention, 13 States, 2013-2017. *MMWR Morb. Mortal. Wkly. Rep.* **68,** 423–429 (2019).

9. McCarthy, F. P., Ryan, R. M. & Chappell, L. C. Prospective biomarkers in preterm preeclampsia: A review. *Pregnancy hypertension* **14,** 72–78 (2018).

10. Roberge, S. *et al.* The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am. J. Obstet. Gynecol.* **216,** 110–120.e6 (2017).

11. Duley, L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* **33,** 130–137 (2009).

12. Hutcheon, J. A., Lisonkova, S. & Joseph, K. S. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol* **25,** 391–403 (2011).

13. Abalos, E., Cuesta, C., Grosso, A. L., Chou, D. & Say, L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **170,** 1–7 (2013).

14. Zhang, J., Meikle, S. & Trumble, A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. *Hypertens Pregnancy* **22,** 203–212 (2003).

15. Steegers, E. A. P., von Dadelszen, P., Duvekot, J. J. & Pijnenborg, R. Pre-eclampsia. *Lancet* **376,** 631–644 (2010).

16. Li, X. *et al.* Hypertensive disorders of pregnancy and risks of adverse pregnancy outcomes: a retrospective cohort study of 2368 patients. *J Hum Hypertens* (2020). doi:10.1038/s41371-020-0312-x

17. Hansen, A. R., Barnés, C. M., Folkman, J. & McElrath, T. F. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. *J. Pediatr.* **156,** 532–536 (2010).

18. Wang, A. *et al.* Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. *J. Matern. Fetal Neonatal Med.* **25,** 1447–1452 (2012).

19. Bellamy, L., Casas, J.-P., Hingorani, A. D. & Williams, D. J. Pre-eclampsia and risk of

cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*
335, 974 (2007).

20. Ahmed, R., Dunford, J., Mehran, R., Robson, S. & Kunadian, V. Pre-eclampsia and future
cardiovascular risk among women: a review. *J. Am. Coll. Cardiol.* **63,** 1815–1822 (2014).

21. Vikse, B. E., Irgens, L. M., Leivestad, T., Skjaerven, R. & Iversen, B. M. Preeclampsia and
the risk of end-stage renal disease. *N. Engl. J. Med.* **359,** 800–809 (2008).

22. McDonald, S. D., Han, Z., Walsh, M. W., Gerstein, H. C. & Devereaux, P. J. Kidney disease
after preeclampsia: a systematic review and meta-analysis. *Am. J. Kidney Dis.* **55,** 1026–
1039 (2010).

23. Hypertension in pregnancy. Report of the American College of Obstetricians and
Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet. Gynecol.* **122,** 1122–1131
(2013).

24. Goel, A. *et al.* Epidemiology and mechanisms of de novo and persistent hypertension in the
postpartum period. *Circulation* **132,** 1726–1733 (2015).

25. Zeisler, H. *et al.* Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected
Preeclampsia. *N. Engl. J. Med.* **374,** 13–22 (2016).

26. Sovio, U. *et al.* Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to
Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous
Women. *Hypertension* **69,** 731–738 (2017).

27. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. *Obstet.*
Gynecol. **135,** e237–e260 (2020).

28. Roberge, S. *et al.* Early administration of low-dose aspirin for the prevention of preterm and
term preeclampsia: a systematic review and meta-analysis. *Fetal Diagn Ther* **31,** 141–146
(2012).

29. Henderson, J. T., Vesco, K. K., Senger, C. A., Thomas, R. G. & Redmond, N. Aspirin use to
prevent preeclampsia and related morbidity and mortality: updated evidence report and
systematic review for the US preventive services task force. *JAMA* **326,** 1192–1206 (2021).

30. Whitehead, C. L., Walker, S. P. & Tong, S. Measuring circulating placental RNAs to non-
invasively assess the placental transcriptome and to predict pregnancy complications.
Prenat. Diagn. **36,** 997–1008 (2016).

31. Munchel, S. *et al.* Circulating transcripts in maternal blood reflect a molecular signature of
early-onset preeclampsia. *Sci. Transl. Med.* **12,** (2020).

32. Tsang, J. C. H. *et al.* Integrative single-cell and cell-free plasma RNA transcriptomics
elucidates placental cellular dynamics. *Proc. Natl. Acad. Sci. USA* **114,** E7786–E7795
(2017).

33. Del Vecchio, G. *et al.* Cell-free DNA Methylation and Transcriptomic Signature Prediction
of Pregnancies with Adverse Outcomes. *Epigenetics* **16,** 642–661 (2021).

34. Phipps, E. A., Thadhani, R., Benzing, T. & Karumanchi, S. A. Pre-eclampsia: pathogenesis,
novel diagnostics and therapies. *Nat. Rev. Nephrol.* **15,** 275–289 (2019).

35. Pennington, K. A., Schlitt, J. M., Jackson, D. L., Schulz, L. C. & Schust, D. J. Preeclampsia:
multiple approaches for a multifactorial disease. *Dis. Model. Mech.* **5,** 9–18 (2012).

36. Burton, G. J., Redman, C. W., Roberts, J. M. & Moffett, A. Pre-eclampsia: pathophysiology
and clinical implications. *BMJ* **366,** l2381 (2019).

37. von Dadelszen, P., Magee, L. A. & Roberts, J. M. Subclassification of preeclampsia.
Hypertens Pregnancy **22,** 143–148 (2003).

38. Huppertz, B. Placental origins of preeclampsia: challenging the current hypothesis.

Hypertension **51,** 970–975 (2008).

39. Raymond, D. & Peterson, E. A critical review of early-onset and late-onset preeclampsia.
Obstet Gynecol Surv **66,** 497–506 (2011).

40. Chaiworapongsa, T. *et al.* Differences and similarities in the transcriptional profile of
peripheral whole blood in early and late-onset preeclampsia: insights into the molecular
basis of the phenotype of preeclampsiaa. *J Perinat Med* **41,** 485–504 (2013).

41. Leavey, K. *et al.* Unsupervised placental gene expression profiling identifies clinically
relevant subclasses of human preeclampsia. *Hypertension* **68,** 137–147 (2016).

42. Benton, S. J., Leavey, K., Grynspan, D., Cox, B. J. & Bainbridge, S. A. The clinical
heterogeneity of preeclampsia is related to both placental gene expression and placental
histopathology. *Am. J. Obstet. Gynecol.* **219,** 604.e1-604.e25 (2018).

43. Koh, W. *et al.* Noninvasive in vivo monitoring of tissue-specific global gene expression in
humans. *Proc. Natl. Acad. Sci. USA* **111,** 7361–7366 (2014).

44. Vorperian, S. K., Moufarrej, M. N., Consortium, T. S. & Quake, S. R. Cell types of origin in
the cell free transcriptome in human health and disease. *BioRxiv* (2021).
doi:10.1101/2021.05.05.441859

45. Gillich, A. *et al.* Capillary cell-type specialization in the alveolus. *Nature* **586,** 785–789
(2020).

46. Arck, P. C. & Hecher, K. Fetomaternal immune cross-talk and its consequences for maternal
and offspring's health. *Nat. Med.* **19,** 548–556 (2013).

47. Uzun, A., Triche, E. W., Schuster, J., Dewan, A. T. & Padbury, J. F. dbPEC: a
comprehensive literature-based database for preeclampsia related genes and phenotypes.
Database (Oxford) **2016,** (2016).

48. Ostlund, I., Haglund, B. & Hanson, U. Gestational diabetes and preeclampsia. *Eur. J.*
Obstet. Gynecol. Reprod. Biol. **113,** 12–16 (2004).

49. Schneider, S., Freerksen, N., Röhrig, S., Hoeft, B. & Maul, H. Gestational diabetes and
preeclampsia--similar risk factor profiles? *Early Hum. Dev.* **88,** 179–184 (2012).

50. Nerenberg, K. A. *et al.* Risks of gestational diabetes and preeclampsia over the last decade
in a cohort of Alberta women. *J Obstet Gynaecol Can* **35,** 986–994 (2013).

51. Weissgerber, T. L. & Mudd, L. M. Preeclampsia and diabetes. *Curr Diab Rep* **15,** 9 (2015).

52. Rey, E. & Couturier, A. The prognosis of pregnancy in women with chronic hypertension.
Am. J. Obstet. Gynecol. **171,** 410–416 (1994).

53. McCowan, L. M., Buist, R. G., North, R. A. & Gamble, G. Perinatal morbidity in chronic
hypertension. *Br J Obstet Gynaecol* **103,** 123–129 (1996).

54. Sibai, B. M. *et al.* The impact of prior preeclampsia on the risk of superimposed
preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension.
Am. J. Obstet. Gynecol. **204,** 345.e1-6 (2011).

55. Uhlen, M. *et al.* A genome-wide transcriptomic analysis of protein-coding genes in human
blood cells. *Science* **366,** (2019).

56. Han, X. *et al.* Differential dynamics of the maternal immune system in healthy pregnancy
and preeclampsia. *Front. Immunol.* **10,** 1305 (2019).

57. Ander, S. E., Diamond, M. S. & Coyne, C. B. Immune responses at the maternal-fetal
interface. *Sci. Immunol.* **4,** (2019).

58. Szarka, A., Rigó, J., Lázár, L., Beko, G. & Molvarec, A. Circulating cytokines, chemokines
and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex
suspension array. *BMC Immunol.* **11,** 59 (2010).

59. Lisonkova, S. & Joseph, K. S. Incidence of preeclampsia: risk factors and outcomes
associated with early- versus late-onset disease. *Am. J. Obstet. Gynecol.* **209,** 544.e1-
544.e12 (2013).
60. Marić, I. *et al.* Early prediction of preeclampsia via machine learning. *American Journal of*
Obstetrics & Gynecology MFM **2,** 100100 (2020).
61. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression
analysis of RNA-seq data. *Genome Biol.* **11,** R25 (2010).
62. Pan, W. Development of diagnostic methods using cell-free nucleic acids. (Stanford
University, 2016).
63. Moufarrej, M. N., Wong, R. J., Shaw, G. M., Stevenson, D. K. & Quake, S. R. Investigating
Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood
During Gestation. *Front. Pediatr.* **8,** 605219 (2020).
64. Vento-Tormo, R. *et al.* Single-cell reconstruction of the early maternal-fetal interface in
humans. *Nature* **563,** 347–353 (2018).
65. Suryawanshi, H. *et al.* A single-cell survey of the human first-trimester placenta and
decidua. *Sci. Adv.* **4,** eaau4788 (2018).
66. Aizarani, N. *et al.* A human liver cell atlas reveals heterogeneity and epithelial progenitors.
Nature **572,** 199–204 (2019).
67. Stewart, B. J. *et al.* Spatiotemporal immune zonation of the human kidney. *Science* **365,**
1461–1466 (2019).
68. Litviňuková, M. *et al.* Cells of the adult human heart. *Nature* **588,** 466–472 (2020).
69. Mathys, H. *et al.* Single-cell transcriptomic analysis of Alzheimer's disease. *Nature* **570,**
332–337 (2019).
70. Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and
conversions of gene lists (2019 update). *Nucleic Acids Res.* **47,** W191–W198 (2019).
71. Brown, L. D., Cai, T. T. & DasGupta, A. Interval Estimation for a Binomial Proportion. *Stat*
Sci **16,** 101–133 (2001).
72. Ibarra, A. *et al.* Non-invasive characterization of human bone marrow stimulation and
reconstitution by cell-free messenger RNA sequencing. *Nat. Commun.* **11,** 400 (2020).
1158